H3K27 demethylase KDM6B aggravates ischemic brain injury through demethylation of IRF4 and Notch2-dependent SOX9 activation

Lysine demethylase 6B (KDM6B) is a histone H3 lysine 27 (H3K27) demethylase that serves as a key mediator of gene transcription. Although KDM6B has been reported to modulate neuroinflammation after ischemic stroke, its role in ischemic brain injury is yet to be well elucidated. Therefore, this study...

Full description

Saved in:
Bibliographic Details
Main Authors: Lisha Chang (Author), Zhaowang An (Author), Jiang Zhang (Author), Fuling Zhou (Author), Dali Wang (Author), Jian Liu (Author), Yunhe Zhang (Author)
Format: Book
Published: Elsevier, 2021-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_d94d16d3ec9f40eeb857f7307b569af9
042 |a dc 
100 1 0 |a Lisha Chang  |e author 
700 1 0 |a Zhaowang An  |e author 
700 1 0 |a Jiang Zhang  |e author 
700 1 0 |a Fuling Zhou  |e author 
700 1 0 |a Dali Wang  |e author 
700 1 0 |a Jian Liu  |e author 
700 1 0 |a Yunhe Zhang  |e author 
245 0 0 |a H3K27 demethylase KDM6B aggravates ischemic brain injury through demethylation of IRF4 and Notch2-dependent SOX9 activation 
260 |b Elsevier,   |c 2021-06-01T00:00:00Z. 
500 |a 2162-2531 
500 |a 10.1016/j.omtn.2021.01.021 
520 |a Lysine demethylase 6B (KDM6B) is a histone H3 lysine 27 (H3K27) demethylase that serves as a key mediator of gene transcription. Although KDM6B has been reported to modulate neuroinflammation after ischemic stroke, its role in ischemic brain injury is yet to be well elucidated. Therefore, this study aimed to thoroughly demonstrate the molecular mechanism underlying the effect of KDM6B on neurological function and astrocyte response in post-ischemic brain injury. Middle cerebral artery occlusion/reperfusion (MCAO) mouse models were constructed, while the oxygen-glucose deprivation/reperfusion (OGD/R) model was developed in astrocytes to mimic injury conditions. KDM6B was upregulated post-MCAO in mice and in astrocytes following the induction of OGD/R. Silencing of KDM6B resulted in suppressed neurological deficit, reduced cerebral infarction volume, attenuated neuronal cell apoptosis, and disrupted inflammation. Dual-luciferase reporter gene and chromatin immunoprecipitation-quantitative polymerase chain reaction assays revealed that KDM6B inhibited H3K27 trimethylation in the interferon regulatory factor 4 (IRF4) promoter region, resulting in the upregulation of IRF4 expression, which in turn bound to the Notch2 promoter region to induce its downstream factor SRY-related high-mobility group box 9 (SOX9). SOX9 knockdown reversed the effects of KDM6B overexpression on ischemia-triggered brain damage. Based on these findings, we concluded that KDM6B-mediated demethylation of IRF4 contributes to aggravation of ischemic brain injury through SOX9 activation. 
546 |a EN 
690 |a ischemic brain injury 
690 |a lysine demethylase 6B 
690 |a histone H3 lysine 27 trimethylation 
690 |a interferon regulatory factor 4 
690 |a Notch2 
690 |a SRY-related high-mobility group box 9 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Molecular Therapy: Nucleic Acids, Vol 24, Iss , Pp 622-633 (2021) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S2162253121000214 
787 0 |n https://doaj.org/toc/2162-2531 
856 4 1 |u https://doaj.org/article/d94d16d3ec9f40eeb857f7307b569af9  |z Connect to this object online.